Led by John Forrest, MD, Director of Interventional Cardiology and the Structural Heart Disease Program, Yale was the first center in Connecticut and one of the first in New England to offer transcatheter aortic valve replacement (TAVR). Today, Yale performs more transcatheter structural procedures than any center in the region. Investigators in our program have been appointed to lead multicentered national and international studies in the treatments of Aortic Valve Stenosis, Mitral Regurgitation, cerebral embolic protection, and other therapies for valvular heart disease. The Yale Center for Outcomes Research and Education (CORE) presently serves as the data analytic center for the Left Atrial Appendage Occluder (LAAO) RegistryTM and led by Jeptha Curtis, MD, and James Freeman, MD, physicians in interventional cardiology and electrophysiology work together to provide patients with the most advanced options in the developing arena of left atrial appendage closure. The Interventional Cardiology Program at Yale is also engaged in the management of patients with a variety of other structural cardiac abnormalities including: atrial septal defects, patent foramen ovales (PFO), ventricular septal defects, and hypertrophic cardiomyopathy.

Advanced Therapies in the Structural Heart and Valve Program

• TAVR
• MitraClip
• Transcatheter Mitral Valve Replacement
• PFO Closure
• Left Atrial Appendage Closure
• Paravalvular Leak Closure
• Repair of adult congenital heart disease conditions including VSD, ASD, and aortic coarctation.

Advanced Therapies in the Structural Heart and Valve Program

• TAVR
• MitraClip
• Transcatheter Mitral Valve Replacement
• PFO Closure
• Left Atrial Appendage Closure
• Paravalvular Leak Closure
• Repair of adult congenital heart disease conditions including VSD, ASD, and aortic coarctation